Keros Therapeutics opened lower at $9.51, compared with its previous close of $9.54. In the last trading session, the stock traded between $9.44 and $10.54. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Keros Therapeutics is now worth
$ 16.98
Resulting in a loss of
$ 83.02 (83.02%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
66.67%
Hold
33.33%
Sell
0%
Markets Today
Today's Change
+$0.53 (+5.58%)
Day High
$10.54
Day Low
$9.44
Day Open
$9.51
Prev Close
$9.54
Volume
6,00,467
1W Return
-7.03%
1M Return
-13.41%
3M Return
-5.58%
6M Return
-16.14%
1Y Return
-40.40%
Fundamentals
Market Cap ($ Mn)
198
PE Ratio
-
PB Ratio
0.84
PEG Ratio
-
ROE
14.44%
ROCE
14.86%
EPS (TTM)
$0.71
Investment Returns
1 Week
-7.03%
1 Month
-13.41%
3 Months
-5.58%
6 Months
-16.14%
9 Months
-40.89%
Financials
Quarterly
All values in $ Mn
18.2
Jun 25
14.3
Sep 25
0.4
Dec 25
0.4
Mar 26
0.0
Jun 26
40.0
Sep 26
Updates
4Aug
Keros Therapeutics Q2 EPS of $(1.45) misses estimate
Keros Therapeutics missed Q2 EPS estimates with a loss of $(1.45) per share, a 90.79% increase in losses compared to the prior year. While the absolute net loss narrowed to $28.7 million due to reduced R&D spending after transitioning elritercept costs to Takeda, the per-share metric deteriorated significantly.
3mo ago
31Jul
Keros Therapeutics receives $20M Takeda milestone for elritercept
Keros Therapeutics triggers a $20 million milestone payment from Takeda after dosing the first patient in the ELRiSE MDS Phase 3 trial for elritercept. The drug treats anemia in myelodysplastic syndromes. Keros plans to distribute 25% of the net proceeds to shareholders. The broader licensing deal includes a prior $200 million upfront payment and potential milestones exceeding $1.1 billion.
3mo ago
23Jul
Keros Therapeutics CFO Keith Regnante resigns effective Aug. 3
Keros Therapeutics announced the resignation of CFO Keith Regnante, effective Aug. 3, and appointed VP Finance Annita Tanini as interim principal financial officer. The leadership transition was disclosed in a regulatory filing.
3mo ago
26Jun
Keros Therapeutics appoints Anne Prener to Board of Directors
Keros Therapeutics, Inc. has appointed Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026. Prener brings extensive clinical development and executive leadership experience to the clinical-stage biopharmaceutical company. Her appointment is expected to support Keros' pipeline advancement and long-term growth strategy.
